
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitor... Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.37 | 15.5462184874 | 2.38 | 2.8621 | 2.36 | 33465 | 2.6746376 | CS |
4 | -1.16 | -29.6675191816 | 3.91 | 4.03 | 2.01 | 41904 | 2.83876539 | CS |
12 | -2.34 | -45.9724950884 | 5.09 | 7.3 | 2.01 | 263102 | 5.88840251 | CS |
26 | -4.2 | -60.4316546763 | 6.95 | 7.59 | 2.01 | 134273 | 5.87788543 | CS |
52 | -14.75 | -84.2857142857 | 17.5 | 18.5 | 2.01 | 153912 | 10.03220261 | CS |
156 | -45 | -94.2408376963 | 47.75 | 92.5 | 2.01 | 195732 | 23.60834856 | CS |
260 | -391.5 | -99.3024730501 | 394.25 | 449.75 | 2.01 | 224208 | 71.17581245 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.